![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Heart Foundation Research Centre, School of Medical Science, Griffith University, Southport, Queensland, Australia
Received May 15, 2007; accepted September 7, 2007.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
70%, to 7 ± 1 mm Hg) and LDH loss (by 60%, to 11 ± 2 U/g). In contrast, P2Y1 agonism with 50 nM 2-methyl-thio-ATP (2-MeSATP) was ineffective. In the presence of the P2Y antagonist suramin (10 or 200 µM), UTP no longer improved postischemic outcomes. Ischemia also substantially elevated interstitial [UTP], [ATP], and [ADP], potentially activating P2 receptors. This was supported in part by effects of antagonists: 200 µM suramin worsened LDH efflux (53 ± 9 IU/g) and contractile dysfunction (41 ± 2 mm Hg diastolic pressure; 28 ± 3 mm Hg developed pressure), as did P2Y antagonism with either 10 or 100 µM reactive blue 2. However, a 10 µM concentration of suramin failed to alter outcome. P2X antagonism with 10 µM pyridoxal phosphate-6-azo-(benzene-2,4-disulfonic acid and P2X1-selective pyridoxal-
5-phosphate-6-phenylazo-4'-carboxylic acid (MRS2159) (30 µM) was ineffective. Data collectively support cardioprotection with low concentrations of UTP, and they are consistent with P2Y2 involvement. Endogenous nucleotides may also play a protective role, as evidenced by effects of P2 antagonists, although this warrants further investigation.
; Vassort, 2001), with recent evidence implicating P2 purinergic receptors in protection of ischemic or reperfused myocardium (Vassort, 2001; Ninomiya et al., 2002a,b). Although purine nucleotides have been the most widely studied P2 agonists, it is clear pyrimidines such as UTP also possess important regulatory functions. Two recent studies provide evidence that UTP may mediate protective actions in ischemic hearts (Yitzhaki et al., 2006) and hypoxic myocytes (Yitzhaki et al., 2005) from rats. However, not all investigations detect such effects of UTP under similar conditions (Ninomiya et al., 2002b), and a number of issues arise from prior studies, foremost among these being the use of very high UTP concentrations to trigger protection (Ninomiya et al., 2002b; Yitzhaki et al., 2005). These prior studies use levels >2 orders of magnitude above those required to activate the P2Y2 receptors implicated in the responses (von Kügelgen and Wetter, 2000; Jacobson et al., 2002; von Kügelgen, 2006). The physiological (even pathological) relevance of responses to such high agonist levels is questionable, and it is difficult to ascribe effects to specific receptor subtypes, because such concentrations will even activate P2 receptors classified as UTP-insensitive (e.g., P2Y1 receptors). Furthermore, in the only study of intact perfused hearts (Ninomiya et al., 2002b) myocyte death was not assessed, and the primary measure of ischemic outcome (contractile recovery) was complicated by uncontrolled and thus variable heart rate. This renders interpretation of rate-dependent contractile function problematic, potentially explaining lack of effect of UTP in this work (Ninomiya et al., 2002b). Another unresolved issue relates to potential roles of endogenous P2 agonists. Whether ischemia enhances interstitial pyrimidine nucleotide levels sufficiently to activate P2 receptors is not known. Interestingly, recent work does reveal elevated vascular UTP in humans suffering myocardial ischemia (Wihlborg et al., 2006), providing indirect support for cardiac UTP release.
Four inter-related questions emerge regarding UTP and cardiac protection, to be addressed in part here: 1) do low and physiologically relevant concentrations of UTP enhance ischemic tolerance; 2) is observed protection with UTP dependent upon P2 receptor activation; 3) does ischemia trigger significant accumulation of UTP and other P2 agonists in cardiac interstitium; and 4) are these interstitial agonist concentrations sufficient to activate P2 receptors and so modify ischemic tolerance? We tested the ability of 250 nM UTP to modify functional outcomes and cell death following ischemia-reperfusion, assessed the impact of P2 antagonism on UTP responses, characterized the impact of ischemia on cardiac interstitial [UTP], and tested for protection in response to intrinsic P2 agonism [through P2 antagonism with suramin, RB-2, PPADS, and pyridoxal-5-phosphate-6-phenylazo-4'-carboxylic acid (MRS2159)].
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
) and work approved by the Institutional Animal Care and Use Committee. Young male C57/Bl6 mice (16–20 weeks of age) were used in the studies. All animals were allowed at least 4 days of in-house acclimatization before experimental procedures.
Chemicals and Reagents. All drugs used were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). Drug solutions were infused into hearts at 
1% of total coronary flow rate to achieve the final concentrations indicated.
Perfused Heart Preparation. The Langendorff mouse heart model, described and characterized by us previously (Headrick et al., 2001; Peart and Headrick, 2003; Reichelt et al., 2005), was used. Hearts were isolated from 16- to 20-week-old male C57/Bl6 mice (23.4 ± 0.5 g b.wt.; n = 119) anesthetized with 50 mg/kg sodium pentobarbital administered intraperitoneally. After a thoracotomy, hearts were excised into ice-cold perfusion buffer, and the aorta was cannulated and perfused at 80 mm Hg with a Krebs-Henseleit buffer containing 118 mM NaCl, 25 mM NaHCO3, 4.7 mM KCl, 1.2 mM KH2PO4, 2.5 mM CaCl2, 1.2 mM Mg2SO4, 11 mM glucose, 2 mM pyruvate, and 0.5 mM EDTA. Buffer was equilibrated with 95% O2, 5% CO2 at 37°C, giving a pH of 7.4. The left ventricle was vented with a polyethylene drain and a fluid-filled balloon was inserted into the ventricle via the mitral valve. The balloon was connected to a pressure transducer for measurement of ventricular pressure. Hearts were immersed in perfusate at 37°C, and the ventricular balloon was inflated to generate a diastolic pressure of 5 mm Hg. Coronary flow was monitored via a Doppler flow-probe (Transonic Systems Inc., Ithaca, NY) in the aortic perfusion line. Functional parameters were measured and recorded on a four-channel MacLab unit (ADInstruments, Castle Hill, NSW, Australia).
Experimental Protocol. Hearts stabilized for 20 min at intrinsic heart rate were switched to ventricular pacing at 420 beats/min (2-ms pulse duration, amplitude 20% above the pacing threshold) for a further 10 min. Baseline function was then assessed, and 20 min of global ischemia was initiated followed by 45 min of reperfusion. Pacing was terminated during ischemia and reinstated at 2 min of reperfusion (Headrick et al., 2001; Peart and Headrick, 2003). Hearts were either untreated (n = 19) or subjected to P2 purinoceptor antagonism (200 µM suramin, 100 µM RB-2, 50 µM PPADS, or 30 µM MRS2159) applied 15 min before ischemia and for the initial 10 min of reperfusion (n = 8 for each drug), P2 purinoceptor agonism with 250 nM UTP (applied 10 min before ischemia and for the initial 10 min of reperfusion; n = 12), or cotreatment with UTP + suramin (n = 8) according to the same protocols. Upon detection of significant effects of both 200 µM suramin and 100 µM RB-2 on intrinsic ischemic tolerance (see Results), we subsequently assessed effects of lower 10 µM concentrations of these antagonists applied alone (n = 7 for suramin; n = 7 for RB-2) and of 10 µM suramin + 250 nM UTP (n = 9). We additionally studied P2Y1 agonism with 50 nM 2-Me-SATP (n = 11). Because we were principally interested in identifying whether P2 agonism (or antagonism) might modify responses to ischemic insult, we used drug infusion protocols effectively bracketing the ischemic episode and early reperfusion.
For assessment of necrotic cell death, we measured efflux of the intracellular enzyme LDH (Headrick et al., 2001; Peart and Headrick, 2003; Reichelt et al., 2005). Myocardial LDH efflux has been shown to correlate linearly with infarct size in this model (Peart and Headrick, 2003). Coronary effluent was collected on ice, and it was stored at–80°C (7 days) until analysis for LDH via a CytoTox assay kit (Promega Corporation, Annandale, NSW, Australia), a colorimetric assay coupling LDH content to conversion of a tetrazolium salt to a colored formazan product. Total LDH washed from hearts during reperfusion was calculated as the product of LDH content (per milliliter) and total coronary effluent over the measurement period (Headrick et al., 2001; Peart and Headrick, 2003).
Cardiac Microdialysis Assessment of Interstitial Nucleotides. To test for elevations in endogenous P2 agonists in the interstitial compartment, a second group of untreated hearts (n = 14) was instrumented with cardiac microdialysis probes according to the method outlined by us previously (Peart and Headrick, 2000). Probes were constantly perfused at 1 µl/min, and eluents were collected on ice over 10-min periods. After a 60-min stabilization period half of these hearts were subjected to 20-min global ischemia and 45-min reperfusion, whereas the remainder were perfused normally (nonischemic control). Consecutive 10-min samples of dialysate were collected, and the dialysate was frozen at–80°C until analyzed via high-performance liquid chromatography, using an adaptation of prior techniques (Headrick and Willis, 1989; Harrison et al., 1998). In brief, dialysate samples were injected onto a Suplecosil C18S column (maintained at 27°C) and eluted at 1 ml/min using a buffer gradient (60% solution A/40% solution B at 0 min to 40% solution A/60% solution B at 25 min, followed by isocratic elution to 60 min). Solution A consisted of a 10 mM KH2PO4 buffer containing 0.25% MeOH and 10 mM tetrabutylammonium hydroxide, pH 6.9. Solution B consisted of a 50 mM KH2PO4 buffer containing 30% MeOH and 5.3 mM tetrabutylammonium hydroxide, pH 7.0. Eluent absorbance was continuously monitored on a Waters photodiode array detector (Waters, Sydney, NSW, Australia), and nucleotide concentrations were calculated based on comparison with absorbances for known standards run each day of analysis.
Statistical Analysis. Data are presented as mean ± S.E.M. Baseline data and functional outcomes from ischemia in different experimental groups were compared via one-way analysis of variance. When significant effects were identified a Newman-Keuls post hoc test was used for individual comparisons. A value of P < 0.05 was considered significant in all tests.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
). Treatment with UTP failed to modify ventricular contractile function in normoxic hearts. Likewise, most antagonist treatments did not alter contractility, although 100 µM (but not 10 µM) RB-2 did generate a significant increase in force development and inotropic state (Table 1). Interestingly, suramin (at 200 µM) and RB-2 (at both 10 and 100 µM) generated significant elevations in baseline coronary flow, whereas there was a tendency (albeit insignificant) for modestly decreased coronary flow with UTP (Table 1).
|
Effects of Ischemia and UTP on Cardiovascular Function and Cell Death. Ischemia resulted in sustained depression of contractile function over the 45-min reperfusion period (Fig. 1). Diastolic pressure remained elevated at 20 mm Hg (Fig. 1A), and ventricular pressure development recovered to 65% of preischemic levels (Fig. 1B). Coronary flow recovered to slightly less than preischemic levels (Fig. 1C). Ischemia-reperfusion was also associated with significant efflux of LDH (Fig. 2), reflecting necrotic death (Peart and Headrick, 2003).
|
|
Effects of Ischemia on Myocardial Interstitial UTP, ATP, and ADP Concentrations. Based on apparent reduction in ischemic tolerance with 100 µM suramin alone, we assessed release of P2 agonists into the interstitial compartment (Fig. 3). Under normoxic conditions, we were able to detect ATP in most cases; yet, we could not consistently detect ADP or UTP in cardiac microdialysate samples (Fig. 3). However, during 20 min of global ischemia the accumulation of all three nucleotides was significantly enhanced, with ATP levels exceeding those for ADP, and in turn UTP. Nucleotide concentrations peaked within the initial 10 min of ischemia and then declined during the ensuing 10 min (although remaining substantially elevated above normoxic levels). Subsequent reperfusion led to a gradual decline in dialysate UTP, ATP, and ADP levels, such that only ATP remained detectable during the final 20 min of reperfusion. No changes in nucleotide levels were detected in normoxically perfused hearts (Fig. 3).
|
65%) (Fig. 4C). The alternate P2 antagonist RB-2 at 100 µM also worsened contractile dysfunction. Interestingly, although a lower 10 µM concentration of RB-2 also worsened ischemic outcomes, this concentration of suramin was without effect on postischemic functional recovery (Fig. 4), although it remained effective in blocking the protective effects of UTP (Fig. 1). Neither 10 µM PPADS nor 30 µM MRS2159 exerted any effect on postischemic recoveries (Fig. 4).
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
, 2006). However, these findings are not universal (e.g., Ninomiya et al., 2002b), and a number of interesting questions arise from these prior investigations. Here, we confirm P2-mediated cardioprotection in response to submicromolar concentrations of UTP, we document significant accumulation of UTP (together with ATP and ADP) in the interstitium of ischemic hearts, and we show that high levels of the P2 antagonists suramin and RB-2 (and not PPADS or MRS2159) worsen ischemic outcome. Interestingly, although a lower 10 µM concentration of RB-2 also limited postischemic outcome, suramin at this concentration was ineffective. Collectively, these findings evidence cardioprotection via exogenous UTP (involving limitation of ventricular contractile dysfunction and necrosis), and they implicate the P2Y2 receptor as the most likely mediator of this protection. Mixed effects of P2 antagonists alone also support protection via endogenous P2 agonists, although these responses may potentially involve P2-independent effects and they deserve further attention (see below).
P2 Purinoceptors and Cardioprotection. Based on structural similarities the P2Y receptor family is grouped into P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 receptors, and into a dissimilar group containing P2Y12 and P2Y13 receptors (Kunapuli and Daniel, 1998; von Kügelgen and Wetter, 2000; Vassort, 2001; Jacobson et al., 2002). These G-coupled receptors, or their mRNAs, have been localized to cardiomyocytes (Webb et al., 1996), cardiac fibroblasts (Zheng et al., 1998), and vascular smooth muscle and endothelium (Wang et al., 2002), and they are known to regulate the activity of multiple intracellular kinases (von Kügelgen and Wetter, 2000) to modify cellular function. Relatively little work has been undertaken to delineate functions of P2Y purinoceptors in myocardial stress resistance and protection. Unfortunately, delineating contributions of individual P2 subtypes to functional responses in intact tissue is hampered by mixed selectivities of agonists and particularly antagonists (von Kügelgen and Wetter, 2000; Jacobson et al., 2002). Although judicious choice of drug concentration can limit the range of receptor candidates, recent studies of cardiac protection have used very high (3–100 µM) UTP concentrations (Ninomiya et al., 2002b; Yitzhaki et al., 2005), sufficient to maximally activate P2Y2, P2Y4, and P2Y6 receptors, and potentially activate P2Y1 and P2Y11 receptors at which UTP is generally considered a poor agonist (von Kügelgen and Wetter, 2000; Jacobson et al., 2002). Here, we use a low UTP concentration of 250 nM that, based on known potencies (Jacobson et al., 2002), should be selective for P2Y2 receptors but may also activate P2Y4 receptors to a limited extent. Because UTP possesses EC50 values at P2Y1, P2Y6, and P2Y11 receptors as much as 3 orders of magnitude higher than the concentration applied here, these receptors should not be significantly activated. Furthermore, we observed no effects of P2Y1 agonism with 2-MeSATP (see Results). Finally, the 10 and 200 µM concentrations of the nonselective P2Y antagonist suramin shown to inhibit UTP-mediated protection (Fig. 1) should exert greatest effects at P2Y2, P2Y1 (eliminated as a candidate due to lack of effect of 2-MeSATP), and P2Y11 receptors (eliminated as a candidate because of their insensitivity to 250 nM UTP). Collectively, the effects of 250 nM UTP and suramin, and lack of effect of 2-MeSATP, implicate P2Y2 receptor involvement in UTP-dependent cardioprotection.
In contrast to our data, a prior study in rats found that myocardial P2Y activation alone does not generate protection, although endogenous P2 agonists apparently contributed to benefit with ischemic preconditioning (Ninomiya et al., 2002a,b). Limitation of ischemic injury observed here (Figs. 1 and 2) is consistent with UTP-mediated protection of hypoxic cardiomyocytes (Yitzhaki et al., 2005). Furthermore, in the course of the current study, Yitzhaki et al. (2006) published details of infarct-sparing effects of transient UTP pretreatment in an in vivo rat model. These investigators found UTP reduced hypoxia-dependent mitochondrial Ca2+ load in isolated myocytes, potentially underlying observed protection. Reasons for the lack of effect of UTP in the earlier study of Ninomiya et al. (2002b) versus protection observed here and by Yitzhaki et al. (2006) are not known, although high UTP levels used in prior studies raise the possibility of confounding effects of multiple P2Y subtype activation. Moreover, Ninomiya et al. (2002b) did not assess markers of cell death, and heart rate was uncontrolled, complicating interpretation of rate-dependent contractility.
Ischemic Accumulation of Interstitial Nucleotides. Cardiac microdialysis provides a useful tool for monitoring accumulation of signaling compounds in the myocardial interstitium (Harrison et al., 1998; Peart and Headrick, 2000; Ninomiya et al., 2002a). Although some degree of tissue injury is unavoidable in microdialysis studies, and the injury is perhaps exaggerated in small technically challenging models such as the mouse (Peart and Headrick, 2000), our data nonetheless reveal substantial ischemia-specific elevations in UTP, ATP, and ADP in cardiac microdialysate (Fig. 3). Although prior studies have documented similar elevations in ATP and ADP in rat myocardium (Ninomiya et al., 2002a), together with elevations in the related P1 agonist adenosine in rat and mouse hearts (Harrison et al., 1998; Peart and Headrick, 2000), this is the first report of ischemic elevations in myocardial interstitial UTP. Recent observations of vascular accumulation of UTP in patients suffering myocardial ischemia are consistent with cardiac UTP release (Wihlborg et al., 2006).
The source and identity of nucleotides released during ischemia remains unclear: nucleotides may be released from endothelium by G-coupled receptor activation (Yang et al., 1994), from sympathetic and parasympathetic nerve endings (Burnstock and Kennedy, 1986), and from cardiac myocytes during hypoxic or ischemic stress (Forrester and Williams, 1977; Clemens and Forrester, 1980). The changes in interstitial nucleotides observed here could play a regulatory role during or following ischemia: interstitial UTP, ATP, or ADP may all activate G-coupled P2Y receptors (with ATP and ADP additionally modulating ion channel-coupled P2X purinoceptors) in coronary vessels (Strøbaek et al., 1996; Wang et al., 2002), cardiac fibroblasts (Zheng et al., 1998), and myocytes (Webb et al., 1996). Although it is problematic to estimate precise solute concentrations from microdialysate levels, our data suggest that low micromolar levels of UTP and ATP may be achieved with severe ischemic stress, sufficient to activate P2Y2 receptors at which these nucleotides possess EC50 values 0.25 µM (Jacobson et al., 2002).
Modulation of Ischemic Tolerance by P2 Antagonism. Having established that low levels of exogenous UTP trigger P2-dependent cardioprotection (Figs. 1 and 2) and that ischemia generates substantial elevations in this and other P2 agonists (Fig. 3), we sought to identify effects of endogenous nucleotides via cotreatment with differing P2 antagonists (Fig. 4). Suramin, RB-2, and PPADS are relatively broad-spectrum antagonists, with RB-2 exhibiting some selectivity for P2Y versus. P2X, whereas PPADS is partially selective for P2X versus P2Y receptors (Jacobson et al., 2002; von Kügelgen, 2006). The drug MRS2159 is selective at P2X1 receptors. It is worth noting that suramin and PPADS can exert effects on signal transduction and G proteins (Shehnaz et al., 2000). However, the polar nature of the agents prevents them from crossing the cell membrane, minimizing these effects in intact tissue.
Detrimental effects of 200 µM suramin and 10 to 100 µM RB-2 on postischemic recovery (Figs. 1 and 4), together with lack of effect of PPADS and MRS2159, tend to support intrinsic activation of P2Y purinoceptors. Since suramin selectively blocks P2Y2 versus P2Y4 receptors (at which it exhibits very poor potency) (von Kügelgen and Wetter, 2000; von Kügelgen, 2006), inhibitory effects of this agent on both UTP-mediated protection and intrinsic ischemic tolerance support involvement of P2Y2 receptors. Lack of effect of PPADS on ischemic outcome is also consistent with P2Y2 involvement, because PPADS is most potent at P2Y1 and possibly P2Y6 receptors, but it is ineffective at rodent P2Y4 and human P2Y2 receptors (von Kügelgen and Wetter, 2000; von Kügelgen, 2006). In contrast, RB-2 will more broadly antagonize P2Y receptor subtypes, and it is also shown to affect on postischemic recovery at low and high concentrations (Fig. 4). However, a complication in this interpretation relates to potential blockade of ectonucleotidase activity by suramin and other P2 antagonists.
Several studies confirm that different P2 antagonists may noncompetitively inhibit ectonucleotidase activity in different species and tissues (Chen et al., 1996; Yegutkin and Burnstock, 2000). Studying Mg2+-sensitive ectonucleotidase from rats, Yegutkin and Burnstock (2000) arrived at an IC50 of 20 to 30 µM for suramin (with values of 50 µM for RB-2 and 1 mM for PPADS). Chen et al. (1996) acquired IC50 values of 40 to >100 µM for suramin in rat and mouse cells (and 15–20 µM for both RB-2 and PPADS). These inhibitory effects will limit responses mediated by hydrolysis products of extracellular nucleotides, which may be responsible (at least in part) for the detrimental actions of these agents during ischemia-reperfusion. In assessing this possibility, we examined responses to lower 10 µM concentrations of suramin and RB-2 (Figs. 1 and 4), which we reasoned should retain some P2 inhibitory efficacy but be less effective in inhibiting ectonucleotidases. It is interesting that, although the lower RB-2 concentration still effectively impaired postischemic outcome, 10 µM suramin was without effect on the response to ischemia (Fig. 4). This likely stems from differing inhibitory potencies of the two agents at different P2 receptors (see above), but it may additionally reflect effects of suramin on other processes dictating postischemic outcome (including inhibition of ectonucleotidase activity) at high concentrations. In this regard, preliminary findings of Eckle et al. (2006) reveal that gene ablation of CD73 worsens outcome from ischemia in vivo, and we have recently confirmed that P1 receptor activation by endogenous adenosine (which is generated via CD73 activity) does limit injury during ischemia-reperfusion (Reichelt et al., 2005). We must temper our conclusion then, that effects of the P2 antagonist suramin may involve a combination of receptor antagonism and/or inhibition of beneficial actions of ectonucleotidase activity. Future work might address the impact of these agents on interstitial accumulation of nucleotides and their hydrolysis products.
Injurious effects of suramin and RB-2 in ischemic myocardium have not been documented previously. The studies of Ninomiya et al. (2002a,b) in rat hearts do not report on effects of P2 antagonism alone, and in any case they use an index of postischemic outcome that is difficult to interpret (rate-dependent contractile function in unpaced hearts). However, other evidence does support endogenous P2 receptor activation or roles for nucleotides in ischemic myocardium: cardiac tissue plasminogen activator release during ischemia is modulated by endogenous nucleotides acting at P2Y receptors (Olivecrona et al., 2007); intrinsic P2 receptor activation contributes to preconditioning with transient ischemia (Ninomiya et al., 2002a); and as already noted, CD73 knockout may worsen ischemic tolerance (Eckle et al., 2006), supporting a contribution of extracellular nucleotide hydrolysis to cardiac protection. Thus, there is evidence for roles of endogenous nucleotides in ischemic myocardium.
P2 Purinoceptor-Dependent Coronary Constriction. Unexpected coronary dilation in response to suramin and RB-2 is of interest because both antagonists significantly enhanced coronary flow in normoxic hearts (Table 1). Additionally, and perhaps related, the P2 agonist UTP elicited a small (albeit insignificant) decline in baseline flow. There is some prior support for P2Y-mediated smooth muscle constriction, in addition to dilation (Corr and Burnstock, 1991; Murthy and Makhlouf, 1998), although substantial species differences exist in these responses. This may explain the modest dilatory effect of extremely high (50 µM) UTP reported by Ninomiya et al. (2002b) in rat hearts versus modest (insignificant) constriction observed with UTP in the mouse (Table 1). Other studies report on novel UTP-sensitive coronary P2Y receptors exhibiting some properties relevant to the current observations (Hill and Sturek, 2002), and they support UTP-mediated coronary constriction (Matsumoto et al., 1997). Rayment et al. (2007) most recently presented evidence for P2Y2-dependent UTP-mediated coronary artery contraction, which is sensitive to suramin. Thus, despite P2-mediated endothelium-dependent dilation of intact vessels (Vials and Burnstock, 1994; Marrelli, 2001), evidence also reveals a P2Y-mediated coronary constriction (Matsumoto et al., 1997; Sugimura et al., 2000). The nature of these different vascular responses deserves further attention, as does the identity of P2 receptors involved. For example, although evidence is presented for P2Y2 involvement in coronary constriction (Rayment et al., 2007), P2Y6-dependent contraction detected in other vessel types (Malmsjö et al., 2003) could conceivably play some role.
Conclusions. This study builds on prior evidence of UTP-mediated tissue protection (Yitzhaki et al., 2005, 2006). Our observations reveal that low concentrations of UTP improve postischemic outcomes in a P2-dependent manner. Although the receptor subtype(s) involved remains to be unequivocally identified, the P2Y2 subtype is most strongly implicated based on the effects of UTP and suramin. Ischemia itself also triggers elevations in interstitial UTP and other P2 agonists (ATP and ADP) to active levels, and P2 antagonism with suramin and RB-2 does limit intrinsic ischemic tolerance. Concentration-dependent actions of suramin warrant further study, and they may reflect differing potency at relevant P2 receptors and/or other inhibitory actions (such as blockade of ectonucleotidase activity).
|
Footnotes |
|---|
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
ABBREVIATIONS: RB-2, reactive blue 2; PPADS, pyridoxal phosphate-6-azophenyl-2', 4'-disulfonic acid; 2-MeSATP, 2-methylthio-ATP; LDH, lactate dehydrogenase; LV, left ventricular; MRS2159, pyridoxal-5-phosphate-6-phenylazo-4'-carboxylic acid.
Address correspondence to: Dr. John P. Headrick, School of Health Science, Griffith University Gold Coast Campus, Southport, QLD 4217, Australia. E-mail: j.headrick{at}griffith.edu.au
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Burnstock G and Kennedy C (1986) Purinergic receptors in the cardiovascular system. Prog Pharmacol 6: 111–132.
Chen BC, Lee CM, and Lin WW (1996) Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages. Br J Pharmacol 119: 1628–1634.[Medline]
Clemens MG and Forrester T (1980) Appearance of adenosine triphosphate in the coronary sinus effluent from isolated working rat heart in response to hypoxia. J Physiol 312: 143–158.
Corr L and Burnstock G (1991) Vasodilator response of coronary smooth muscle to the sympathetic co-transmitters noradrenaline and adenosine 5'-triphosphate. Br J Pharmacol 104: 337–342.[Medline]
Eckle T, Grenz A, Faigle M, Weissmuller T, Thompson L, Colgan SP, Oßwald H, and Eltzschig HK (2006) Critical role of 5'-ectonucleotidase (CD73) in cardiac ischemic preconditioning (Abstract). Purinergic Signal 2: 164.
Forrester T and Williams CA (1977) Release of adenosine triphosphate from isolated adult heart cells in response to hypoxia. J Physiol 268: 371–390.
Harrison GJ, Willis RJ, and Headrick JP (1998) Extracellular adenosine levels and cellular energy metabolism in ischemically preconditioned rat heart. Cardiovasc Res 40: 74–87.
Headrick JP, Peart J, Hack B, Flood A, and Matherne GP (2001) Functional properties and responses to ischemia reperfusion in Langendorff perfused mouse hearts. Exp Physiol 86: 703–716.
Headrick JP and Willis RJ (1989) 5'-Nucleotidase activity and adenosine formation in stimulated, hypoxic and underperfused rat heart. Biochem J 261: 541–550.[Medline]
Hill BJF and Sturek M (2002) Pharmacological characterization of a UTP-sensitive P2Y nucleotide receptor in organ cultured coronary arteries. Vasc Pharmacol 39: 83–88.[CrossRef]
Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
Jacobson KA, Jarvis MF, and Williams M (2002) Purine and pyrimidine (P2) receptors as drug targets. J Med Chem 45: 4057–4093.[CrossRef][Medline]
Kunapuli SP and Daniel JL (1998) P2 receptor subtypes in the cardiovascular system. Biochem J 336: 513–523.[Medline]
Malmsjö M, Hou M, Pendergast W, Erlinge D, and Edvinsson L (2003) Potent P2Y6 receptor mediated contractions in human cerebral arteries. BMC Pharmacol 3: 4.[CrossRef][Medline]
Marrelli SP (2001) Mechanisms of endothelial P2Y1- and P2Y2-mediated vasodilatation involve differential [Ca2+]i responses. Am J Physiol 281: H1759–H1766.
Matsumoto T, Nakane T, and Chiba S (1997) UTP induces vascular responses in the isolated and perfused canine epicardial coronary artery via UTP-preferring P2Y receptors. Br J Pharmacol 122: 1625–1632.[CrossRef][Medline]
Murthy KS and Makhlouf GM (1998) Coexpression of ligand-gated P2X and G protein-coupled P2Y receptors in smooth muscle. Preferential activation of P2Y receptors coupled to phospholipase C (PLC)-
1 via Gaq/11 and to PLC-3 via G
i3. J Biol Chem 273: 4695–4704.
Ninomiya H, Otani H, Lu K, Uchiyama T, Kido M, and Imamura H (2002a) Complementary role of extracellular ATP and adenosine in ischemic preconditioning in the rat heart. Am J Physiol Heart Circ Physiol 282: H1810–H1820.
Ninomiya H, Otani H, Lu K, Uchiyama T, Kido M, and Imamura H (2002b) Enhanced IPC by activation of pertussis toxin-sensitive and -insensitive G protein-coupled purinoceptors. Am J Physiol 282: H1933–1943.
Olivecrona GK, Gotberg M, Harnek J, Jacobson KA, Jern S, and Erlinge D (2007) The ADP receptor P2Y1 mediates t-PA release in pigs during cardiac ischemia. J Thromb Thrombolysis 24: 115–122.[CrossRef][Medline]
Peart J and Headrick JP (2000) Intrinsic activation of A1 adenosine receptors during ischemia and reperfusion improves ischemic tolerance. Am J Physiol 279: H2166–H2175.
Peart J and Headrick JP (2003) Adenosine-mediated early preconditioning in mouse: protective signaling and concentration dependent effects. Cardiovasc Res 58: 589–601.
Rayment SJ, Latif ML, Ralevic V, and Alexander SP (2007) Evidence for the expression of multiple uracil nucleotide-stimulated P2 receptors coupled to smooth muscle contraction in porcine isolated arteries. Br J Pharmacol 150: 604–612.[CrossRef][Medline]
Reichelt M, Willems L, Molina JG, Sun C-X, Noble JC, Ashton KJ, Schnermann J, Blackburn MR, and Headrick JP (2005) Genetic deletion of the A1 adenosine receptor limits myocardial ischemic tolerance. Circ Res 96: 363–367.
Strøbaek D, Olesen SP, Christophersen P, and Dissing S (1996) P2-purinoceptor-mediated formation of inositol phosphates and intracellular Ca2+ transients in human coronary artery smooth muscle cells. Br J Pharmacol 118: 1645–1652.[Medline]
Sugimura A, Kanatsuka H, Tanikawa T, Ong BH, and Shirato K (2000) Effect of diadenosine tetraphosphate (AP4A) on coronary arterial microvessels in the beating canine heart. Jpn Circ J 64: 868–875.[CrossRef][Medline]
Vassort G (2001) Adenosine 5'-triphosphate: a P2-purinergic agonist in the myocardium. Physiol Rev 81: 767–806.
Vials AJ and Burnstock G (1994) Differential effects of ATP- and 2-methylthio ATP-induced relaxation in guinea pig coronary vasculature. J Cardiovasc Pharmacol 23: 757–764.[Medline]
von Kügelgen I (2006) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 110: 415–432.[CrossRef][Medline]
von Kügelgen I and Wetter A (2000) Molecular pharmacology of P2Y-receptors. Naunyn Schmiedebergs Arch Pharmacol 362: 310–323.[CrossRef][Medline]
Wang LW, Karlsson L, Moses S, Hultgardh-Nilsson A, Andersson M, Borna C, Gudbjartsson T, Jern S, and Erlinge D (2002) P2 receptor expression profiles in human vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 40: 841–853.[CrossRef][Medline]
Webb TE, Boluyt MO, and Barnard EA (1996) Molecular biology of P2Y purinoceptors: expression in rat heart. J Auton Pharmacol 16: 303–307.[Medline]
Wihlborg AK, Balogh J, Wang L, Borna C, Dou Y, Joshi BV, Lazarowski E, Jacobson KA, Arner A, and Erlinge D (2006) Positive inotropic effects by uridine triphosphate (UTP) and uridine diphosphate (UDP) via P2Y2 and P2Y6 receptors on cardiomyocytes and release of UTP in man during myocardial infarction. Circ Res 98: 970–976.
Yang S, Cheek YS, Westfall DP, and Buxton IL (1994) Purinergic axis in cardiac blood vessels. Agonist-mediated release of ATP from cardiac endothelial cells. Circ Res 74: 401–407.
Yegutkin GG and Burnstock G (2000) Inhibitory effects of some purinergic agents on ecto-ATPase activity and pattern of stepwise ATP hydrolysis in rat liver plasma membranes. Biochim Biophys Acta 1466: 234–244.[Medline]
Yitzhaki S, Shainberg A, Cheporko Y, Vidne BA, Sagie A, Jacobson KA, and Hochhauser E (2006) Uridine-5'-triphosphate (UTP) reduces infarct size and improves rat heart function after myocardial infarct. Biochem Pharmacol 72: 949–955.[CrossRef][Medline]
Yitzhaki S, Shneyvays V, Jacobson KA, and Shainberg A (2005) Involvement of uracil nucleotides in protection of cardiomyocytes from hypoxic stress. Biochem Pharmacol 69: 1215–1223.[CrossRef][Medline]
Zheng JS, O'Neill L, Long X, Webb TE, Barnard EA, Lakatta EG, and Boluyt MO (1998) Stimulation of P2Y receptors activates c-fos gene expression and inhibits DNA synthesis in cultured cardiac fibroblasts. Cardiovasc Res 37: 718–728.
This article has been cited by other articles:
|
|
 |
|
  U. Gergs, P. Boknik, W. Schmitz, A. Simm, R.-E. Silber, and J. Neumann A positive inotropic effect of ATP in the human cardiac atrium Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1716 - H1723. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
